Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study

NCT03603288 is registered in ClinicalTrials.gov with Santhera Pharmaceuticals as lead sponsor.

NCT NCT03603288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03603288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
Lead sponsor
Santhera Pharmaceuticals
Phase
Phase 3
Overall status
Terminated
Start date
July 4, 2018
Completion date
November 25, 2020
Enrollment
161 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy